open access

Vol 62, No 4 (2005)
Other
Published online: 2005-12-12
Submitted: 2012-12-28
Get Citation

Antioxidant effects of combined vitamins C and E in acute myocardial infarction. The randomized, double-blind, placebo controlled, multicenter pilot Myocardial Infarction and VITamins (MIVIT) trial

Tomasz Jaxa-Chamiec, Bronisław Bednarz, Dorota Drozdowska, Jacek Gessek, Jacek Gniot, Krzysztof Janik, Teresa Kawka-Urbanek, Paweł Maciejewski, Michał Ogórek, Michał Szpajer
Kardiol Pol 2005;62(4):344-350.

open access

Vol 62, No 4 (2005)
Other
Published online: 2005-12-12
Submitted: 2012-12-28

Abstract

Aims. There is a large body of evidence that reactive oxygen species (ROS) produced during myocardial ischemia and reperfusion play a crucial role in myocardial damage and endothelial dysfunction. The MIVIT pilot trial was designed to test the effects of antioxidant vitamins C and E on the clinical outcome of patients with AMI. Methods and results. In this randomized, double-blind, multicenter trial, 800 patients (mean age 62) with AMI were randomly allocated to receive, on top of routine medication, one of two treatments: vitamin C (1000 mg/12 h infusion) followed by 1200 mg/24 h orally and vitamin E (600 mg/24 h) or matching placebo for 30 days. Primary end point (composite of in-hospital cardiac mortality, non-fatal new myocardial infarction, VT/VF/asystole, shock/pulmonary edema) occurred less frequently in patients treated with antioxidants (55 [14%] vs 75 [19%], OR 0.82 [95% CI, 0.68-1.00], p=0.048). Conclusions. This randomized pilot trial shows that supplementation with antioxidant vitamins is safe and seems to positively influence the clinical outcome of patients with AMI. A larger study is warranted to provide further evidence of this promising and inexpensive regimen.

Abstract

Aims. There is a large body of evidence that reactive oxygen species (ROS) produced during myocardial ischemia and reperfusion play a crucial role in myocardial damage and endothelial dysfunction. The MIVIT pilot trial was designed to test the effects of antioxidant vitamins C and E on the clinical outcome of patients with AMI. Methods and results. In this randomized, double-blind, multicenter trial, 800 patients (mean age 62) with AMI were randomly allocated to receive, on top of routine medication, one of two treatments: vitamin C (1000 mg/12 h infusion) followed by 1200 mg/24 h orally and vitamin E (600 mg/24 h) or matching placebo for 30 days. Primary end point (composite of in-hospital cardiac mortality, non-fatal new myocardial infarction, VT/VF/asystole, shock/pulmonary edema) occurred less frequently in patients treated with antioxidants (55 [14%] vs 75 [19%], OR 0.82 [95% CI, 0.68-1.00], p=0.048). Conclusions. This randomized pilot trial shows that supplementation with antioxidant vitamins is safe and seems to positively influence the clinical outcome of patients with AMI. A larger study is warranted to provide further evidence of this promising and inexpensive regimen.
Get Citation

Keywords

MYOCARDIAL INFARCTION – FREE RADICALS – ANTIOXIDANT VITAMINS – PROGNOSIS

About this article
Title

Antioxidant effects of combined vitamins C and E in acute myocardial infarction. The randomized, double-blind, placebo controlled, multicenter pilot Myocardial Infarction and VITamins (MIVIT) trial

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 62, No 4 (2005)

Pages

344-350

Published online

2005-12-12

Bibliographic record

Kardiol Pol 2005;62(4):344-350.

Keywords

MYOCARDIAL INFARCTION – FREE RADICALS – ANTIOXIDANT VITAMINS – PROGNOSIS

Authors

Tomasz Jaxa-Chamiec
Bronisław Bednarz
Dorota Drozdowska
Jacek Gessek
Jacek Gniot
Krzysztof Janik
Teresa Kawka-Urbanek
Paweł Maciejewski
Michał Ogórek
Michał Szpajer

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl